Cell-Based Drug Toxicity and Efficacy Testing

Neurons under drug toxicity testing

Physiologically relevant cell line models and cell-based in vitro assays are becoming crucial tools for screening new drug candidates before moving to expensive testing using animal model. The development of cutting-edge new technologies such as CRISPR/Cas9 and induced pluripotent stem cell (iPSC) technologies has enabled the engineering of predictive and reliable in vitro disease models which afford an inexpensive, faster, efficient, and ethically compatible alternative to using costly, animal models for preliminary drug screening. 

Make Informed Go-No-Go Decisions Early in Your Drug Development! Process! Applied StemCell (ASC), an ISO-certified service provider offers a flexible assay platform with a wide-range of functional endpoints for early-stage in vitro screening of preclinical drug candidates. We use a comprehensive cell-based test battery from which you can choose assays for efficacy, safety or target discovery that suit your therapeutic pipeline. We will provide the scientific expertise, accurate and efficient screening to help you take informed decisions about your small/ large molecules early in your drug development process to avoid costly drug attrition.      

1. In Vitro Disease Modeling

Genome Editing/ Correction
 (Cancer cells, iPSCs, ESCs, primary cells)

iPSC Reprogramming & Differentiation

3D Cell/ iPSC Culture

button-gray-forward-arrow 

2. Drug Screening

Phenotypic Screening

Functional Validation

Cell Viability/ Toxicity

Mitochondrial/ Hepatic/Cardio Toxicity

Customized Assay Development

 

1. In Vitro Disease Modeling:

Screen your compounds in a wide-variety of cell lines! Applied StemCell is a market leader in gene editing technologies. We can engineer > 100 distinct cell lines with a wide variety of mutations, using a combination of different technologies (CRISPR/Cas9, TARGATT™ and more) and techniques (transfection/transduction) to generate many different cell line models that are perfectly suited to screen candidate compounds in your therapeutic pipeline.

 We also provide comprehensive iPSC services and products for iPSC-based neurotoxicity & efficacy screening:

2. Drug Screening:

Flexible/ customizable project options to suit your screening needs! Below is a sample list of some of the assays we offer.

(Don’t see an assay you want? CONTACT US with your project requirements.)

Screening

Types of Assays

Estimated Timeline

Cytotoxicity & Cell Viability Assays

MTT/ MTS cell proliferation assay

LDH, Necrosis and Apoptosis assays

Luciferase (bioluminescence) expression

cAMP level measurement

4-6 weeks

Mitochondrial Toxicity Testing

Enzyme activity

Volume fraction detection

2-4 weeks

Functional Assays

Calcium influx/ imaging

Electrophysiology: Multielectrode array (MEA) analysis and Patch clamp recording

8-12 weeks

Quantitative Gene Expression

qPCR

RNA-seq using NGS (next generation sequencing)

2-8 weeks

Morphology

Neurite growth assay

Biomarker screening

2-4 weeks

Custom Assays

iPSC generation; characterization; gene editing; differentiation

Custom assay development

Based on project requirements

Our custom screening service is ideal for CNS, cardiovascular, metabolic, cancer, and immunotherapy drug candidates.

References

Publications

  • Vozdek, R., Long, Y., & Ma, D. K. (2018). HIR-1 Mediates Response to Hypoxia-Induced Extracellular Matrix Remodeling. bioRxiv, 302638. doi: https://doi.org/10.1101/302638
Ordering